Lucerastat - CAS 141206-42-0

Lucerastat (NBDGJ) is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates.

Transferase

Metabolism

141206-42-0

0.98

C10H21NO4

219.28

C(CCC)N1[C@H](CO)[C@H](O)[C@H](O)[C@@H](O)C1

-20°C

Ice Packs

Small Compound